Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat in relapsed/refractory solid tumors or hematological malignancies by UGT1A1 genotype
NCT02680795Phase 1Completed
- Sponsor
- Acrotech Biopharma Inc
- Start
- Apr 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of belinostat in solid tumor and hematological malignancies (3 cohorts), sponsored by Acrotech Biopharma Inc. Primary endpoints: Plasma concentrations of belinostat and Urine concentrations of belinostat. Started Apr 2016; status: completed.
02
Drugs
belinostat
03
Conditions
solid tumorhematological malignancies
Beyond the preview
Go deeper on NCT02680795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680795.